Niferin SR 30mg Tablet

البلد: ماليزيا

اللغة: الإنجليزية

المصدر: NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

العنصر النشط:

NIFEDIPINE

متاح من:

Abio Marketing Sdn Bhd

INN (الاسم الدولي):

NIFEDIPINE

الوحدات في الحزمة:

30tablet Tablets; 28tablet Tablets

المصنعة من قبل:

CHINA CHEMICAL & PHARMACEUTICAL CO., LTD.

خصائص المنتج

C
max
(ng/ml)
t
max
(h)
20 ~
12 ~ 15 *
43 ~
7 ~ 9 *
NIFERIN SR 30MG TABLET
COMPOSITION:
Each Tablet contains:
Nifedipine
30 mg
PRODUCT
DESCRIPTION:
A round tablet with rose-pink film and a small laser orifice on the
surface
PHARMACOLOGY:
Nifedipine is a calcium antagonist of the
1,4-dihydropyridine
type.
Calcium antagonists reduce the transmembranal influx of calcium
ions through the slow calcium channel into the cell. Nifedipine
acts particularly on the cells of the myocardium and the smooth
muscle cells of the coronary arteries and the peripheral vessels.
In the heart nifedipine dilates the coronary arteries, especially the
large
conductance vessels,
even
in
the
free
wall
segment
of
partially stenosed areas. Further, nifedipine reduces the vascular
smooth
muscle
tone
in
the
coronary
arteries
and
prevent
vasospasm. The end-result is an increased poststenotic blood flow
and an increased oxygen supply.
Parallel to
this, nifedipine
reduces the oxygen requirement by lowering peripheral resistance
(afterload). With long-term use nifedipine can also prevent the
development
of
new
atherosclerotic
lesions
in
the
coronary
arteries.
Nifedipine reduces the smooth muscle tone of the arterioles, thus
lowering the increased peripheral resistance and consequently the
blood pressure.
At
the
beginning of the
nifedipine treatment there
may
be
a
transient reflex increase in heart rate and thus in the cardiac
output.
However,
this
increase
is
not
enough
to
compensate
for
the
vasodilation. In addition nifedipine increases sodium and water
excretion both in the short-term and long-term use. The blood-
pressure-lowering
effect of nifedipine is particularly pronounced in
hypertensive
patients.
PHARMACOKINETICS
Niferin SR 30mg tablets are formulated to provide nifedipine at an
approximately constant rate over 24 hours. Nifedipine is released
from the tablet at a zero-order rate by a membrane-controlled,
osmotic push-pull process. The delivery rate is independent of
gastrointestinal pH or motility. Upon swallowing, the biologically
inert